<p>Reduction in Risk of Stroke and Systemic Embolism in Non-valvular AF-</p>

<ul>
	<li>CrCl &gt;30 mL/min: 150 mg twice daily</li>
	<li>CrCl 15 to 30 mL/min: 75 mg twice daily</li>
	<li>CrCl &lt;15 mL/min or on dialysis: Dosing recommendations cannot be provided</li>
	<li>CrCl 30 to 50 mL/min with concomitant use of P-gp inhibitors: Reduce dose to 75 mg twice daily if given with P-gp inhibitors dronedarone or systemic ketoconazole.</li>
	<li>CrCl &lt;30 mL/min with concomitant use of P-gp inhibitors: Avoid co-administration</li>
</ul>

<p>Treatment of DVT and PE, Reduction in the Risk of Recurrence of DVT and PE-</p>

<ul>
	<li>CrCl &gt;30 mL/min: 150 mg twice daily</li>
	<li>CrCl &le;30 mL/min or on dialysis: Dosing recommendations cannot be provided</li>
	<li>CrCl &lt;50 mL/min with concomitant use of P-gp inhibitors: Avoid co-administration</li>
</ul>

<p>Prophylaxis of DVT and PE Following Hip Replacement Surgery-</p>

<ul>
	<li>CrCl &gt;30 mL/min: 110 mg for first day, then 220 mg once daily</li>
	<li>CrCl &le;30 mL/min or on dialysis: Dosing recommendations cannot be provided</li>
	<li>CrCl &lt;50 mL/min with concomitant use of P-gp inhibitors: Avoid co-administration.</li>
</ul>

<p><br />
<strong>Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</strong>: For patients with creatinine clearance (CrCl) &gt;30 mL/min, the recommended dose of Dabigatran Etexilate is 150 mg taken orally, twice daily. For patients with severe renal impairment (CrCl 15-30 mL/min), the recommended dose of Dabigatran Etexilate is 75 mg twice daily. Dosing recommendations for patients with a CrCl &lt;15 mL/min or on dialysis cannot be provided.<br />
<br />
<strong>Treatment of Deep Venous Thrombosis and Pulmonary Embolism</strong>: For patients with CrCl &gt;30 mL/min, the recommended dose of Dabigatran Etexilate is 150 mg taken orally, twice daily, after 5-10 days of parenteral anticoagulation. Dosing recommendations for patients with a CrCl &le;30 mL/min or on dialysis cannot be provided.<br />
<br />
<strong>Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism</strong>: For patients with CrCl &gt;30 mL/min, the recommended dose of Dabigatran Etexilate is 150 mg taken orally, twice daily after previous treatment. Dosing recommendations for patients with a CrCl &le;30 mL/min or on dialysis cannot be provided.<br />
<br />
<strong>Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism Following Hip Replacement Surgery</strong>: For patients with CrCl &gt;30 mL/min, the recommended dose of Dabigatran Etexilate is 110 mg taken orally 1-4 hours after surgery and after hemostasis has been achieved, then 220 mg taken once daily for 28-35 days. If Dabigatran Etexilate is not started on the day of surgery, after hemostasis has been achieved initiate treatment with 220 mg once daily. Dosing recommendations for patients with a CrCl &le;30 mL/min or on dialysis cannot be provided</p>